Chengdu Olymvax Stock Hits Day Low of CNY 23.10 Amid Price Pressure

Chengdu Olymvax Biopharmaceuticals, Inc. experienced a notable decline today, with the stock dropping by 5.02% and reaching an intraday low of CNY 23.10. This midcap player in the Pharmaceuticals & Biotechnology sector has faced significant pressure, particularly over the past week, where it has seen a decrease of 13.34%. In a broader context, the stock's performance over the past month has been particularly challenging, with a decline of 39.26%, contrasting sharply with the China Shanghai Composite's decrease of just 5.31% during the same period. Despite these recent setbacks, the company has shown resilience over the past year, achieving a positive return of 8.29%, outperforming the China Shanghai Composite's 5.99% gain. Financial metrics indicate a strong operational foundation, with a net sales growth of 25.38% reported in September. The company has also maintained a robust interest coverage ratio of 1,289.5 and a return on capital employed (ROCE) of 6.86%. However, the stock's long-term performance remains mixed, with a five-year decline of 26.63%, while it has outperformed the composite index over three years.